Scientists probe genetic secrets of lung cancer relapse after key drug

NCT ID NCT06477055

Recruiting now Knowledge-focused Sponsor: Hunan Province Tumor Hospital Source: ClinicalTrials.gov ↗

First seen Apr 19, 2026 · Last updated May 16, 2026 · Updated 2 times

Summary

This study examines the genetic changes in early-stage lung cancer that comes back after treatment with the drug osimertinib. Researchers will analyze tumor or blood samples from 60 adults whose cancer has returned. The goal is to better understand why recurrence happens, not to test a new treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hunan Provincal Tumor Hospital
RECRUITING

Changsha, Hunan, 410013, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
The Second Affiliated Hospital Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310009, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER